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ABSTRACT
Background: The extent to which sustained caloric restriction (CR) in healthy 
non-obese adults is safe has not been previously investigated.
Objective: Assess the safety and tolerability of sustained two-year CR intervention 
in healthy, non-obese adults. 
Design: A multi-center, randomized controlled trial. Participants were randomized 
using a 2:1 allocation in favor of 25% CR vs. Ad-Libitum intake (AL). Adverse and 
serious adverse events (AE, SAE), safety laboratory tests, and other safety parameters 
were closely monitored. 
Results: Three participants were withdrawn from the CR intervention because of 
the safety concerns. No deaths and one SAE was reported by participants in the CR 
group. Although the difference in AE between AL and CR groups was not significant, 
within the CR group, the incidence of nervous system (p = 0.02), musculoskeletal (p 
= 0.02) and reproductive system (p = 0.002) disorders was significantly higher in 
the normal-weight than in the overweight participants. At months 12 and 24, bone 
mineral densities at the lumbar spine, total hip, and femoral neck of participants in 
the CR group were significantly lower than in those in the AL group. 
Conclusions: Two-years of CR at levels achieved in CALERIE was safe and well 
tolerated. Close monitoring for excessive bone loss and anemia is important.
INTRODUCTION
Numerous studies have shown that caloric restriction 
(CR) increases mean and maximum lifespan in many, but 
not all models [1-3]. In many rodent strains, non-human 
primates, and humans, CR decreases the risk for and 
delays the onset of diseases and conditions associated 
with aging, including diabetes, cardiovascular disease and 
cancer [3-5]. The overall aim of the recently completed 
Comprehensive Assessment of Long-Term Effects of 
Reducing Intake of Energy (CALERIE) study was to 
test the hypothesis that sustained for two years caloric 
restriction in healthy men aged 21 to 50 and healthy 
women aged 21 to 47 will result in adaptive changes 
analogous to those that occur in rodents subjected to CR. 
The adaptive responses thought to be involved in slowing 
the aging process and protecting against age-related 
diseases were of particular interest. Effects of two years 
of sustained CR on primary, secondary and a number of 
related outcomes are reported separately [6]. As the extent 
to which sustained CR in healthy non-obese adults might 
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be successful but accompanied by unacceptable adverse 
effects has not been previously investigated. We here 
report on one of the secondary objectives of CALERIE, 
which was to systematically examine the safety of CR 
intervention in non-obese healthy adults. 
RESULTS 
Achieved levels of caloric restriction
As described [6], on average, in an intent-to-treat 
analysis, daily energy intake declined from baseline in 
CR group by 480 kcal/d during the first six months of 
intervention, then stabilized at approximately 234 kcal/d 
below baseline for the remainder of the trial, resulting in 
CR averaging 11.9% over two years (19.5±0.8% during 
the first six months and 9.1±0.7% on average for the 
remainder of the study, p<.0001 vs. AL).
Study and intervention discontinuations
The baseline characteristics of 218 participants 
included in the safety analyses are summarized in Table 
1 and details on screening, recruitment and retention 
are published elsewhere [6, 7]. A total of 30 participants 
(26 in the CR and 4 in the AL group) discontinued from 
their respective interventions prior to completing the 
study. The 26 CR participants included three women 
who became pregnant during the study, three withdrawn 
for safety reasons (see below), 14 who withdrew consent 
or discontinued participation for other reasons, and 
six participants relocated prior to study completion. 
Three participants in the CR group were permanently 
discontinued from the intervention but completed all 
follow-up evaluations and were included in the safety 
analysis. In the control group, three women became 
pregnant, one participant withdrew consent, and all four 
were permanently discontinued. Those who failed to 
provide complete information tended to be younger and 
better educated (p = 0.01 for both); otherwise, there were 
no significant differences with respect to demographic and 
other baseline characteristics [6].
Adverse events and serious adverse events
Overall, a total of 3,332 adverse events were 
reported in the study. In the CR group, 95.1% of 
participants reported a total of 1,995 events and a total 
of 1,337 events were reported by 96.0% of participants 
enrolled in the AL group. Seven participants reported a 
total of eight serious adverse events during the study. Of 
these, one event (spontaneous miscarriage) was reported 
by a participant in the CR group and seven (pneumothorax, 
uterine leiomyoma, scoliosis, spinal osteoarthritis, 
intestinal abscess, small intestinal obstruction, and atrial 
septal defect) were reported by participants in the AL 
group. All AL participants who experienced the SAEs 
completed the study. 
In 11 MedDRA System Organ Classes (SOCs), 10% 
or more of participants in either group experienced at 
least one non-serious adverse event. These SOCs included 
infections and infestations; nervous system disorders; 
psychiatric disorders; musculoskeletal and connective 
tissue disorders; gastrointestinal disorders; general 
disorders; respiratory, thoracic and mediastinal disorders; 
reproductive disorders; injury, poisoning and procedural 
complications; immune system disorders; and skin and 
subcutaneous tissue disorders. Only reproductive system 
disorders (24.5% CR vs. 14.7% AL) and skin disorders 
(15.4% CR vs. 10.7% AL) were reported more frequently 
by CR participants. However, differences between the 
treatment groups were not statistically significant (p=0.12 
and p=0.41, respectively). A total of 28 specific AEs in 10 
MedDRA organ classes were reported by 10% or more 
of participants in either treatment group. Among AE’s 
that were reported in 5% or more of participants in either 
treatment group, the incidence of 13 individual AEs in 
8 MedDRA organ classes was higher in the CR than in 
the AL group, but none of the differences between the 
treatment arms reached statistical significance (Table 2).
Of interest is the incidence of AEs in the CR group 
by BMI and duration of the intervention. In the CR group, 
in all 11 MedDRA SOCs which occurred in 10% or more 
of participants in either group, incidence of adverse 
events was higher in normal-weight than in overweight 
participants (Table 3). For nervous, musculoskeletal and 
reproductive system disorders, the incidence was 20 
percentage points higher in normal-weight participants. 
These differences were statistically significant (p=0.016, 
p=0.014 and p=0.001, respectively). In the control group, 
only incidence of immune system disorders was 20 
percentage points higher in overweight than in normal-
weight participants (31.6% and 10.8%, respectively, 
p=.047). In both CR and control groups, a higher 
proportion of normal weight than overweight women 
reported dysmenorrhea (25.9% vs 14.6% and 18.5% vs 
9.5%m respectively). Among the individual events which 
occurred more often in the CR group than the AL group, 
and in at least 5% of the CR subjects, the incidence of 
eight out of 13 individual events was noticeably higher 
in the first year of the study with about twice as many 
participants in the first year reporting dysmenorrhea, 
dizziness, diarrhea, and constipation (Figure 1). In the 
control group, reporting pattern was the same with about 
twice as many participants in the first year reporting 
dysmenorrhea, dizziness, diarrhea, and constipation (not 
shown).
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Safety laboratory test results
A higher proportion of participants in the CR than in 
the control group had higher than normal serum creatine 
kinase levels and mean cell volume during the study. In 
several participants on several occasions creatine kinase 
levels increased up to 10 times above the upper limit 
of normal. Lower than normal levels of the eGFR, total 
hemoglobin, hematocrit, mean corpuscular hemoglobin, 
platelet and white blood cell count as well as serum iron 
and sodium were observed more often in the CR group. 
However, most of the abnormalities were small, with levels 
slightly below the lower limit of normal and none of the 
differences between the treatment arms reached statistical 
significance (Table 4). Unlike incidence of the AEs 
which was higher in the normal weight CR participants, 
incidence of select abnormal laboratory tests was higher in 
the overweight than in the normal-weight CR participants 
(not shown). Approximately 45% of the overweight 
participants experienced increased levels of serum creatine 
kinase while this abnormality was observed only in 29.4% 
of the normal-weight participants. Correspondingly, 
9.3% and 20.0% of the overweight participants reported 
decreases in hematocrit and sodium levels vs. 4.4% and 
7.4% of the normal-weight participants, respectively. 
In the control group, a higher proportion of the normal-
weight than the overweight participants reported increases 
in creatine kinase levels (37.8% vs 29%) and decrease in 
hematocrit levels (11% vs 0%). No difference in levels of 
sodium was observed between the treatment arms. 
Table 1: Demographic, anthropometric and clinical characteristics at baseline for the 218 participants who are 
included in safety analysis
Males (n = 66) Females (n = 152) Overall  (n = 218)
Characteristic AL (n = 22) CR (n = 44) AL (n = 53) CR (n = 99) AL (n = 75) CR (n = 143)
Age, y 37.8 (7.1)1 40.5 (7.2) 37.9 (6.9) 36.8 (7.2) 37.9 (7.0) 38.0 (7.3)
Race:
White 18 (81.8%)2 37 (84.1%) 39 (73.6%) 74 (74.7%) 57 (76.0%) 111 (77.6%)
African-American 1 (4.6%) 2 (4.6%) 10 (18.9%) 13 (13.1%) 11 (14.7%) 15 (10.5%)
Other 3 (13.6%) 5 (11.4%) 4 (7.6%) 12 (12.1%) 7 (9.3%) 17 (11.9%)
Height, m 176.7 (5.3) 177.1 (7.2) 165.0 (6.8) 165.2 (6.4) 168.4 (8.3) 168.9 (8.6)
Baseline Weight, kg 79.8 (6.6) 81.6 (8.3) 68.0 (6.9) 67.7 (6.3) 71.5 (8.7) 72.0 (9.5)
Baseline BMI, kg/m2 25.6 (1.7) 26.0 (1.6) 24.9 (1.6) 24.8 (1.7) 25.1 (1.6) 25.2 (1.8)
Body Fat, % 25.7 (4.0) 26.1 (3.1) 36.8 (4.2) 36.0 (4.3) 33.6 (6.6) 32.9 (6.1)
FFM, kg 59.3 (5.2) 60.3 (6.0) 42.8 (3.6) 43.2 (4.1) 47.6 (8.6) 48.5 (9.2)
FM, kg 20.5 (3.9) 21.3 (3.7) 25.2 (4.8) 24.4 (4.3) 23.8 (5.0) 23.5 (4.3)
Waist Circumference, cm 88.5 (5.5) 89.0 (5.5) 78.3 (5.5) 77.0 (5.5) 81.3 (7.2) 80.7 (7.8)
Systolic BP, mmHg 117.9 (7.6) 116.2 (8.2) 108.4 (9.4) 110.3 (10.1) 111.2 (9.9) 112.1 (9.9)
Diastolic BP, mmHg 73.2 (7.6) 73.6 (7.5) 70.4 (6.8) 71.4 (7.5) 71.2 (7.1) 72.1 (7.5)
Contraception:
Tubal ligation - - 5 (9.4%)2 8 (8.1%) 5 (9.4%) 8 (8.1%)
Hysterectomy - - 2 (3.8%) 5 (5.1%) 2 (3.8%) 5 (5.1%)
Oral - - 10 (18.9%) 23 (23.2%) 10 (18.9%) 23 (23.2%)
Barrier/Condom - - 11 (20.8%) 16 (16.2%) 11 (20.8%) 16 (16.2%)
Other3 - - 17 (32%) 30 (30.3%) 17 (32%) 30 (30.3%)
None/Unknown - - 8 (15%) 17 (17.2%) 8 (15%) 17 (17.2%)
Bone mineral density, 
z-score
Lumbar spine 0.1 ± 1.0 -0.0±1.0 -0.7±1.7 -0.3±1.0 -0.5 ± 1.5 -0.2 ± 1.0
Total hip 0.2 ±0.8 -0.1±0.8 -0.1±0.8 -0.0±0.9 -0.0 ± 0.8 -0.0 ± 0.8
Femoral neck 0.1± 0.9 -0.1±0.9 -0.3±0.9 -0.2±0.9 -0.2 ± 0.9 -0.2 ± 0.9
1 Mean (s.d.)
2 n (%)
AL = Ad libitum treatment group; CR = Caloric Restricted treatment group; s.d. = standard deviation; FFM = fat free mass; 
FM = fat mass, BP = blood pressure
3 Includes contraceptive vaginal ring "NuvaRing™," barrier method plus spermicide, intrauterine device, spousal vasectomy, 
abstinence, and natural family planning
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Electrocardiogram
No clinically significant ECG abnormalities were 
observed at any time point during the study. The most 
commonly reported abnormality was bradycardia, which 
could be considered a favorable effect of caloric restriction 
due to decreased sympathetic or thyroid tone [8]. 
Physical examination and vital signs
There were no clinically significant abnormalities 
observed during the physical examination nor were there 
any clinically significant changes in vital signs observed 
during the study.
Depression
Five (3.5%) participants in the CR group and 1 
participant (1.3%) in the control group had BDI scores 
suggestive of moderate depression. No BDI scores 
suggestive of the severe depression were observed. As 
prescribed in the depression surveillance protocol, all 
six participants were further evaluated by a licensed 
professional to confirm or reject the diagnosis. No 
participants discontinued the CR intervention or the study 
because of depression.
Eating disorders. There was a screening protocol 
to exclude any study candidates who displayed signs of 
eating disorder pathology. During the study, participants 
were monitored for signs of eating disorders using two 
questionnaires - Multi-axial Assessment of Eating 
Disorder Symptoms [9] and Body Acceptability Morph 
[10]. Ninety-four (65.7%) CR participants who had scores 
suggestive of eating disorders at some point during the 
study were administered the Interview for the Diagnosis of 
Eating Disorders-Fourth Version, but no eating disorders 
were confirmed and no further actions were taken. Thirty 
nine (52%) of participants in the control group had scores 
suggestive of eating disorder at some point during the 
study. 
Excessive bone loss
At month 12 and 24, the BMD at lumbar spine, total 
hip and intertrochanter of participants in the CR group 
was significantly lower than in those in the control group 
(p<0.001 for the between-group differences at all sites). 
The BMD at femoral neck and trochanter was also lower 
in the CR group compared to participants in the control 
group at month 12 (p=0.0022 and p=0.0023, respectively 
by site) and month 24 (p=0.034 and p=0.0026, respectively 
by site) visits. There were no differences in BMD at the 
whole body and distal radius between the CR group and 
control group. Because of the excessive bone loss, two CR 
participants discontinued the intervention temporarily and 
one other permanently.
Drop in hematocrit levels
The anemia and hematocrit surveillance protocol 
was triggered when there was a decrease in hemoglobin, 
hematocrit, or red blood cells below the lower limit 
of normal (LLN) or a decrease of 5 percentage points 
in hematocrit level (even if it stayed within the normal 
range). There were 99 such episodes among 35 CR 
participants (24.5%). The hematocrit drop resolved before 
Table 2: Incidence and number of non-serious adverse events reported more frequently by participants in the CR 
group, and in at least 5% of CR participants.
Preferred Term Ad Libitum (n = 75) Caloric restriction (n = 143) p – value3% (pts)1 No. events2 % (pts) 1 No. events2
Sinus congestion 10.7 17 16.1 43 0.31
Dysmenorrhea 15.1 31 21.2 78 0.40
Dizziness 12.0 14 14.7 48 0.68
Diarrhea 13.3 16 14.0 27 1.00
Nasal congestion 6.7 14 13.3 28 0.17
Constipation 6.7 11 12.6 44 0.25
Toothache 8.0 12 11.9 21 0.49
Muscle strain 4.0 4 10.5 16 0.12
Gastroenteritis viral 6.7 5 9.1 16 0.61
Pain 6.7 10 8.4 20 0.79
Rash 1.3 1 6.3 9 0.17
Urinary tract infection 5.3 6 5.6 11 1.00
1 Percent of participants who experienced at least one event
2 Total number of AEs (includes multiple events from the same participant) 
3 Fisher’s exact test comparing the incidence (proportion of patients) reporting at least one adverse events between the two 
treatment groups at specific preferred term level only
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the end of the study in 18 participants; two participants 
were withdrawn for treatment-resistant decreases in 
hematocrit while 7 others withdrew for other reasons; and, 
in 8 participants, it did not resolve completely but they 
remained in the study. In the control group, there were 
34 episodes among 17 participants (23%) triggering the 
anemia surveillance protocol. 
DISCUSSION
CALERIE was the first study in healthy non-
obese adults between the ages of 21 years and 50 
years at screening that developed and implemented a 
comprehensive surveillance protocol to assess the safety 
of two years’ sustained caloric restriction. Our results 
show that sustained caloric restriction at levels achieved 
in CALERIE was safe and well tolerated. No deaths 
were observed in the study. One serious adverse event, 
a miscarriage, was reported in the CR group but its 
relationship to the intervention was considered doubtful. 
Only in two MedDRA system organ classes, reproductive 
system and skin disorders, participants in the CR group 
reported more non-serious events than participants 
in the control group, but none of the difference were 
statistically significant. Correspondingly, none of the 
differences between the treatment arms for the twelve 
individual non-serious events that were reported more 
often by participants in the CR group reached statistical 
significance. Of interest is the higher incidence of adverse 
events in normal weight than in overweight participants 
with differences between the BMI strata reaching 
statistical significance for the nervous, musculoskeletal 
and reproductive system disorders. However, because 
the total number of participants in each BMI strata was 
small, no definitive inferences about the effects of BMI on 
the incidence of adverse events could be made and more 
studies are needed to answer this question. There also 
were not enough data to conclude that a higher incidence 
of select adverse events observed in the first year of the 
study indicated that the potentially negative effects of CR 
would manifest early after initiation of the intervention. 
This is confounded, however, with lower adherence to the 
CR intervention in the second year. Overall, non-serious 
adverse events reported more often by participants in the 
CR group appear to be minor and do not pose a safety 
hazard. 
It is well established that weight loss in obese adults 
is accompanied by loss of BMD: about 10% weight loss 
results in 1% to 4 % loss of BMD at the hip or lumbar spine 
[11-14]. CALERIE showed that in younger non-obese 
adults, weight loss predictably was also accompanied by 
modest BMD loss at the clinically relevant sites, although 
the clinical significance of a change in 0.16 T-score units 
is unclear. Using the World Health Organization’s Fracture 
Risk Assessment tool, we estimated that such degree of 
BMD loss in a middle-aged non-obese woman would 
Table 3: Incidence and number of non-serious adverse events reported by participants in the CR group by system 
organ class and BMI
Overall (n = 143) Normal weight (n = 68) Overweight (n = 75) p – value3System Organ Class % (pts)1 No. events2 % (pts) 1 No. events2 % (pts) 1 No. events2
Overall 95.1 1995 97.1 1164 93.3 831 0.45
Infections & infestations 62.2 239 67.6 133 57.3 106 0.23
Nervous system disorders 58.7 508 69.1 347 49.3 161 0.02
Musculoskeletal & 
connective tissue disorders 52.4 224 63.2 137 42.7 87 0.02
Gastrointestinal disorders 51.7 289 60.3 137 44.0 152 0.07
General disorders 48.3 188 52.9 109 44.0 79 0.32
Respiratory, thoracic & 
mediastinal disorders 41.3 178 44.1 97 38.7 81 0.61
Injury, poisoning & 
procedural complications 28.7 67 30.9 33 26.7 34 0.59
Reproductive disorders 24.5 133 36.8 77 13.3 56 0.002
Reproductive disorders 
(women only)4 34.3 132 41.4 76 24.4 56 0.09
Immune system disorders 16.1 47 17.6 26 14.7 21 0.66
Skin & subcutaneous tissue 
disorders 15.4 30 19.1 18 12.0 12 0.26
Psychiatric disorders 16.8 49 17.6 25 16.0 24 0.83
1 Percent of participants who experienced at least one event
2 Total number of AEs (includes multiple events from the same participant) 
3 Fisher’s exact test comparing the incidence (proportion of patients) reporting at least one adverse events between the two 
BMI strata at system organ class level only
4 n = 99 for all, n = 58 for normal weight and n = 41 for overweight
Oncotarget19129www.impactjournals.com/oncotarget
Table 4: Select laboratory test abnormalities observed more frequently in participants enrolled in the CR group
Laboratory Test
Ad Libitum (n = 75) Caloric restriction (n = 143)
p – value3% (pts)1 No. occurrences2 % (pts) 
1 No. occurrences2
Creatine kinase (high) 33.3 36 37.8 123 0.56
Mean cell volume (high) 14.7 23 18.2 68 0.57
White blood cells (low) 20.0 38 27.3 124 0.25
Sodium (low) 10.7 11 14.0 29 0.53
Iron (low) 5.3 5 9.8 17 0.31
eGFR (low) 4.0 7 6.3 14 0.55
Hemoglobin (low) 4.0 5 7.7 30 0.39
Hematocrit (low) 5.3 6 7.0 23 0.78
Platelet count (low) 2.7 5 5.6 23 0.50
Mean corpuscular hemoglobin 2.7 4 4.9 38 0.72
1 Percent of participants with at least one abnormal laboratory test result above (“high”) the upper limit of normal or below 
(“low”) the lower limit of normal
2 Total number of occurrences of a specific laboratory test abnormality 
3 Fisher’s exact test comparing the incidence (proportion of patients) with at least one abnormality between the two treatment 
groups at specific laboratory test level only
Figure 1: Individual adverse events in CR participants in years 1 and 2 of CALERIE. Includes only AEs that occurred 
more often in the CR arm and were reported by at least 5% of CR participants.
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increase her 10-year risk of osteoporotic fracture by 
about 0.2%. The increase in fracture risk associated with 
the lowering of BMD in CALERIE appears to be very 
small, but longer term studies would be needed to fully 
assess the clinical importance of these findings. Whether 
this amount of bone loss accompanied by weight loss is 
physiologically significant is unclear.
Safety laboratory tests showed that CR in healthy 
non-obese adults at levels achieved in CALERIE 
increased the risk for significant decreases in hematocrit, 
which in some participants required iron supplementation 
or resulted in discontinuation of the CR intervention. 
Increases in levels of creatine kinase observed in some 
participants in the CR group could be explained by a 
significant loss of muscle mass, but data are insufficient to 
confirm or reject this hypothesis and further studies would 
be needed. 
We also compared the safety laboratory test 
abnormalities observed in the CALERIE Phase 1 studies 
with findings from the current CALERIE study. While 
some of the changes in the safety laboratory tests observed 
in CALERIE Phase 1 studies were also observed in the 
current CALERIE study, some were not. At one of the 
clinical sites participating in CALERIE Phase 1 studies, 
hyperkalemia was observed in a large proportion of 
participants, but less than 5% of the CR participants in the 
current trial developed this abnormality. There were also 
concerns about CR participants developing hypocalcemia 
but no cases were observed in the current CALERIE study. 
In both Phase 1 and Phase 2 (current) CALERIE studies a 
higher proportion of participants in the CR than in the AL 
group showed decreases in hemoglobin, hematocrit and 
serum iron levels. 
No eating disorders were diagnosed in the study 
and no participants discontinued the CR intervention 
because of depression. A careful screening of the study 
candidates and exclusion of any who showed the signs of 
eating disorders or depression could have contributed to 
this outcome. 
Although CALERIE is the largest study to date 
on the effects of sustained caloric restriction in healthy 
non-obese adults, the total number of participants 
remains relatively small, thus the power remains low to 
make definitive conclusions about the safety of CR in 
this population can be made. Also, because CALERIE 
population is highly selective, safety findings from this 
study cannot be extrapolated to the general population. 
Another potential limitation is that CALERIE utilized the 
safety measures that are standard in pharmaceutical trials. 
It is possible that studies on effects of caloric restriction 
in humans require monitoring of a different set of safety 
parameters which are as yet not well-defined. Finally, 
there data are insufficient to assess the clinical significance 
of the observed effects of CR on risk factors for diseases 
associated with aging versus the clinical significance of 
the observed increases in risk for anemia and excessive 
bone loss. Based upon available information, we conclude 
that in future studies of sustained caloric restriction in non-
obese healthy individuals close monitoring for excessive 
BMD loss and anemia is important.
MATERIALS AND METHODS
Study design and Intervention
CALERIE was a two year multi-center, parallel-
group, randomized controlled trial; the full details have 
been published [15]. Randomization was stratified by 
gender and body mass index (BMI) within each clinical 
center, with BMI dichotomized into normal weight (22.0 
to 24.9 kg/m2) and overweight (25.0 to 27.9 kg/m2). A 
2:1 allocation ratio in favor of the CR intervention was 
applied in order to maximize the number of participants 
receiving the CR intervention. Given the nature of the 
study interventions, neither the participants nor the 
CALERIE intervention staff were blinded to the treatment 
assignments. However, staff evaluating study endpoints 
was blinded and communications between the two groups 
of staff members were minimized. The monitoring of 
adherence to the intervention was driven by a target 
trajectory of weight loss reaching 15.5% below baseline 
after one year of intervention followed by maintenance 
of this weight over the second year of the study. This 
trajectory was modeled after CALERIE phase 1 pilot 
studies data that predicted the expected changes in body 
weight for participants adherent to a one year 25% CR. 
The details of the CR intervention have been 
reported previously [16] and were chosen to optimize the 
likelihood that a substantial degree of CR was achieved 
(estimated to be 25% based upon modeling of Phase I 
data). A complete daily vitamin and mineral supplement 
as well as a daily calcium supplement of 1,000 mg were 
provided to both the intervention and ad libitum (AL) 
control group to ensure that participants met the current 
recommendations for these nutrients. 
Participants
A total of 238 healthy, non-obese men aged 21 to 
50 years and women aged 21 to 47 years of different 
races provided written informed consent. Of these, 
220 participants were randomized and 218 started the 
interventions. All 218 participants who started the 
interventions were included in the safety analyses. All 
study candidates were carefully screened to ensure that 
they were free of significant medical conditions, eating 
disorders and depression, did not have a history of alcohol 
and drug abuse, their prespecified safety laboratory 
markers were within the normal range, and they were 
not taking any medications (oral, implantable and 
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vaginal contraceptives were allowed). Study candidates 
with low bone density (BMD) defined as a BMD of the 
total hip, femoral neck, or lumbar spine equal to or less 
than a T-score of -2.3 were excluded from participation. 
Current smokers and those who quit smoking less than 12 
months prior to screening and breast-feeding or pregnant 
women were excluded. After some initial pregnancies 
were reported in the trial, inclusion criteria for all 
women participants required the practice of an effective 
contraception method. Contraception use was verified 
at Month 1, 3, 6, 9, 12, 18, and 24 visits. Acceptable 
forms of contraception included tubal ligation, partial or 
complete hysterectomy, oral contraceptive pills, implanted 
progesterone “Implanon™,” contraceptive vaginal 
ring “NuvaRing™,” barrier method plus spermicide, 
intrauterine device, spousal vasectomy, abstinence, and 
natural family planning when other contraceptive methods 
were prohibited due to religious reasons. Detailed patient 
characteristics, information on participant recruitment, 
screening and retention as well as a complete list of 
eligibility criteria are published elsewhere [6, 7, 15].
Safety measures
Safety of the participants during CALERIE Phase 2 
study was closely monitored by the clinical site physician-
investigators, the study Safety Committee, and by the 
independent Data and Safety Monitoring Board appointed 
by the National Institute on Aging. A complete medical 
history was performed during screening and included a 
review of all major organ systems and all medications 
taken during a 30-day period prior to screening. A 
thorough review of reproductive status, contraceptive 
use and menstrual history for women was performed. 
An abbreviated medical and medication history was 
reviewed at baseline. A complete physical examination 
was performed for each participant at screening, baseline, 
Months 12, and 24 visits. The vital signs included blood 
pressure, oral temperature, respiratory rate and pulse rate 
and were collected at every clinic visit. 
CALERIE used the International Conference on 
Harmonization E2A definitions of adverse event (AE) and 
serious adverse event (SAE) [17]. Participants were given 
diaries to record signs, symptoms and adverse events 
occurring during the study. This included anecdotal reports 
of medical problems such as constipation, dizziness, 
fatigue, pain, nausea and infections, and menstrual 
irregularities for women. In addition to the regularly 
scheduled clinic visits, participants in both treatment 
groups were contacted monthly by study staff either by 
phone or in person to collect the adverse events. Diary-
reported AEs were reviewed by the study staff, and newly 
emerging AEs, as well as the status of any AEs that have 
not yet resolved, were recorded in the case report forms. 
During these contacts, the study staff members proactively 
asked whether any sign, symptom or AEs had occurred 
since the previous contact. All adverse events were coded 
using the Medical Dictionary for Regulatory Affairs 
(MedDRA), version 14.4. 
The safety clinical laboratory tests included 
hematology, clinical chemistry and urinalysis which 
were performed at a central laboratory at baseline and 
follow-up visits at months 1, 3, 6, 9, 12, 18 and 24. 
Hematological tests included white cell count with 
differential, red cell count (RBC), RBC morphology, 
hemoglobin, hematocrit, and platelet count. Serum 
chemistry tests included sodium, potassium, calcium, 
magnesium, iron, albumin, total protein, total bilirubin, 
alanine transaminase, aspartate aminotransferase, gamma-
glutamyl transpeptidase, alkaline phosphatase, creatine 
phosphokinase, creatinine, blood urea nitrogen, estimated 
glomerular filtration rate (eGFR), glucose and uric acid. 
Total, high density lipoprotein - and calculated low density 
lipoprotein cholesterol, triglycerides, C-reactive protein, 
and blood glucose and insulin values were also performed. 
Urinalysis included pH, protein, glucose, ketones, occult 
blood, specific gravity, and a microscopic examination. 
Screening of female participants included a serum 
pregnancy test (serum human chorionic gonadotrophin). A 
urine pregnancy test was performed at baseline and then at 
Months 6, 12, 18 and 24 for CR participants and at Months 
12 and 24 only for controls. This test was also performed 
prior to the Hepatitis A vaccination and booster at Months 
17 and 23. Results of all safety laboratory tests were 
reviewed by a clinical site physician for any abnormalities. 
A standard resting 12-lead electrocardiogram (ECG) 
was recorded at screening, baseline and follow-up visits at 
month 1, 3, 6, 9, 12, 18, and 24 and was reviewed by the 
clinical site physician and a cardiologist. At screening or 
baseline, any candidate who had any of the following ECG 
abnormalities was considered ineligible for the study, and 
the screening process or baseline testing was terminated at 
that point. The abnormalities were signs of hyperkalemia, 
type II second or third degree heart block, ventricular 
ischemia, left bundle branch block, cardiac hypertrophy by 
any criteria, QRS complex > 100 ms in duration, abnormal 
QTc interval, superventricular tachycardia of any type not 
including atrial premature contractions, or ventricular 
arrhythmia of any type (including ventricular premature 
complexes more than 60 per minute), and exercise 
ECG recorded during the maximal oxygen uptake test 
demonstrating any of the above mentioned abnormalities 
occurring with exercise. The ECG protocol provided for 
discontinuation of the CR intervention if any of the ECG 
abnormalities, except for ventricular ischemia occurring 
with exercise, were observed at months 1, 3, 6, 9, 12, 
18, and 24. Such participants would be asked to follow 
all other study procedures to the study end. Ventricular 
ischemia observed with the exercise in a participant 
enrolled in the CR group would result in temporary 
discontinuation of the intervention and a stress imaging 
study would be performed within two weeks. If a stress 
Oncotarget19132www.impactjournals.com/oncotarget
imaging study confirmed presence of ventricular ischemia, 
the CR intervention would be permanently discontinued 
and a participant would be asked to complete all outcome 
assessments to the study end.
There were seven safety surveillance protocols 
developed and implemented by CALERIE Safety 
Committee. The selection of the safety markers was 
informed by findings from CALERIE pilot studies. 
Participants were closely monitored for signs of 
hyperkalemia defined as increase in potassium levels 
above 5.5 mEq/L, significant drop in hematocrit below the 
lower limit of normal, cholesterol levels elevated above 
the upper limit of normal, eating disorders, depression 
and other mental or behavioral health conditions as well 
as excessive weight and bone loss. The protocols provided 
for the correction of these conditions and for temporary or 
permanent discontinuation of the CR intervention where 
indicated. 
The study defined moderate depression as Beck 
Depression Inventory (BDI) score equal to or greater than 
20 and less than 30; correspondingly, severe depression 
was defined as the BDI score of equal to or greater than 
30. 
Prior to the study, there were concerns about a 
possibility of excessive bone loss by CR participants. 
Correspondingly, the Safety Committee in consultation 
with the Data and Safety Monitoring Board and bone 
health experts implemented a comprehensive BMD 
monitoring protocol. In addition, all participants in 
both groups were provided with calcium and vitamin 
D supplements for two years. BMD at the hip, spine 
and forearm was measured with dual-energy X-ray 
absorptiometry (DXA). The hip and spine scans were 
obtained at baseline, 6, 12 and 24 months and were used 
to monitor participants for excessive bone loss (defined as 
BMD decrease of >10% at the total hip or lumbar spine). 
Scans were obtained using a standardized protocol for 
subject positioning, scan mode and analysis. All DXA 
measures were transmitted and assessed by a centralized 
reading center to maintain consistency and reduce 
variability. 
Temporary discontinuation of the CR intervention 
was defined as cessation of the CR regimen for up to 30 
days. The CR intervention was temporary discontinued 
when there was a significant increase in potassium level, 
or participant developed a treatment-resistant drop in 
hematocrit, depression or any other disease or condition 
where restriction in energy intake could interfere with 
the treatment or recovery (e.g., severe infections, 
recovery from trauma or surgery, and similar), or if 
there was a decrease in BMI <18.5 kg/m2. A number of 
newly diagnosed diseases and conditions such as cancer, 
persistent clinical drop in hematocrit, major clinical 
cardiovascular event, eating or psychiatric disorder, 
decrease in BMI below 18.5 kg/m2 or excessive bone 
loss (as defined above) and select clinical laboratory 
test abnormalities required permanent discontinuation 
of the CR intervention. Participants who permanently 
discontinued the CR intervention were strongly 
encouraged to continue the outcome measurements. 
Statistical Methods 
Simple descriptive statistics are used to summarize 
the characteristics of the study population. Between-
group comparisons of the incidence of AEs and laboratory 
abnormalities were performed using Fisher’s exact test. 
A similar approach was applied for differences between 
BMI strata within the CR group. All report p-values are 
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